Elsevier

Biochemical Pharmacology

Volume 24, Issue 21, 1 November 1975, Pages 1953-1957
Biochemical Pharmacology

Research paper
Studies on a ketone reductase in human and rat liver and kidney soluble fraction using warfarin as a substrate

https://doi.org/10.1016/0006-2952(75)90381-0Get rights and content

Abstract

The enantiomers of warfarin were reduced to warfarin alcohols on incubation with human and rat liver and kidney cytosol. The metabolism was NADPH-dependent with NADH being only one tenth as effective at supporting the reduction. R-warfarin was reduced at a greater rate than S-warfarin by each of the tissues examined. At a concentration of 2·08 mM the rate of S-warfarin reduction ranged from 5 to 50% of the rate occurring with R-warfarin in the same tissue fraction. R-warfarin (1·3 mM) was mainly reduced to warfarin alcohol 1 (RS) (77%) the remainder being warfarin alcohol 2 (RR). S-warfarin formed slightly more warfarin alcohol 2 (SS) (57%) than warfarin alcohol 1 (SR). The apparent Km values for the reduction of R-warfarin by human and rat liver and kidney cytosol ranged from 0·54 to 1·55 mM. The human liver reductase, even 3·5–8·5 hr after death, was significantly more active (2 times) than the rat liver reductase. Stability studies using rat liver indicated that about half of the reductase activity activity may be lost during the first 6 hr after death. This would suggest that human liver had more than four times the warfarin reductase activity of rat liver.

References (15)

  • C.A. Lau-Cam et al.

    J. Pharm. Sci.

    (1972)
  • O.H. Lowry et al.

    J. biol. Chem.

    (1951)
  • R.J. Lewis et al.

    Biochem. Med.

    (1970)
  • H.W. Culp et al.

    J. biol. Chem.

    (1968)
  • D.S. Hewick et al.

    J. Pharm. Pharmac.

    (1973)
  • R.J. Lewis et al.

    J. clin. Invest.

    (1974)
  • W.M. Barker et al.

    J. Pharmac. exp. Ther.

    (1970)
There are more references available in the full text version of this article.

Cited by (53)

  • Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases

    2016, Biochemical Pharmacology
    Citation Excerpt :

    The Km for (RR/SS)-warfarin alcohol was similar in both liver fractions, but the microsomes had a higher Vmax. Until now, there have been only two kinetic studies on the in vitro reduction of warfarin in human liver [22,32]. The study by Moreland et al. [32] was performed only with cytosol, using (R)-warfarin as the substrate.

  • Determination of warfarin alcohols by ultra-high performance liquid chromatography-tandem mass spectrometry: Application to in vitro enzyme kinetic studies

    2014, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
    Citation Excerpt :

    Warfarin undergoes reduction by hepatic reductases, which generate warfarin alcohols of two diastereoisomers, namely RS/SR-warfarin alcohol (alcohol 1), and RR/SS-warfarin alcohol (alcohol 2) [10,11]. Warfarin reduction is catalyzed predominantly in the cytosol, producing warfarin alcohol 1 as the major metabolite [12,13]. Although reduction accounts for up to 20% of warfarin metabolism [11] and produces pharmacologically active alcohol metabolites [14], the effect of altered reductase function on the disposition of warfarin and its alcohol metabolites has not been studied to date.

  • Comparative metabolism of warfarin in rats and chickens

    2011, Poultry Science
    Citation Excerpt :

    In particular, an increasing incidence of anticoagulant poisoning in birds has been reported (Eason et al., 2002; Erickson and Urban, 2004). The evident causes in birds are divided into 2 categories: primary exposure by direct consumption of bait, and secondary exposure by consumption of poisoned prey (Albert et al., 2010; Redig and Arent, 2008; Murray and Tseng, 2008). In mammals, warfarin is extensively catalyzed to hydroxywarfarin forms in liver microsomes by hydroxylation reactions in phase 1 metabolic pathways using cytochrome P450 (CYP).

  • Human P450 metabolism of warfarin

    1997, Pharmacology and Therapeutics
View all citing articles on Scopus
View full text